Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636487 | 0.82 | ALOX5 (0.38) | ATMALOX5CHRM3CHRM2CHRM1 | |
| SCHEMBL523847 | 0.82 | ALOX5 (0.41) | ATMALOX5CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL27743790 | 0.81 | ALOX5 (0.40) | ATMALOX5CHRM3CHRM2CHRM1 | |
| SCHEMBL4030050 | 0.80 | ALOX5 (0.37) | ATMNR3C1ALOX5CHRM3CHRM2 | |
| SCHEMBL11795750 | 0.80 | ATM (0.46) | ATMNR3C1ALOX5CHRM3P2RX4 | |
| Bromomethane SCHEMBL208551 | 0.79 | ALOX5 (0.39) | ATMALOX5CHRM3CHRM2CHRM1 | |
| SCHEMBL2596466 | 0.78 | P2RX4 (0.45) | NR3C1ALOX5CHRM3CHRM2CHRM1 | |
| SCHEMBL13672457 | 0.77 | CHRM3 (0.45) | ALOX5CHRM3P2RX4CYP2C9MEN1 | |
| SCHEMBL11996655 | 0.77 | ATM (0.40) | ATMNR3C1ALOX5CHRM3P2RX4 | |
| SCHEMBL27732904 | 0.76 | ATM (0.42) | ATMALOX5CHRM3P2RX4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | claimed |
| EP-1879882-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | claimed |
| EP-2721048-A1 | A PROCESS FOR EXTRACTION OF PEPTIDES AND ITS APPLICATION IN LIQUID PHASE PEPTIDE SYNTHESIS | Lonza Ltd (CH) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171982-A1 | A PROCESS FOR EXTRACTION OF PEPTIDES AND ITS APPLICATION IN LIQUID PHASE PEPTIDE SYNTHESIS | LONZA LTD (CH) | 2012-12-20 | — | — | WO | disclosed |
| EP-1879882-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | ATM 4837/4885NR3C1 2047/4885ALOX5 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.